Inter-individual variability in clinical efficacy of different biological treatments in psoriatic patients, has been observed. Thus, the identification of a blood-based biomarker able to foresee the therapeutic response to treatment is urgently needed, especially considering the high cost of biological therapies. MicroRNAs (miRs) deregulation were previously observed in psoriatic patients, and increasing evidence highlighted that miRs could be novel biomarkers not only with diagnostic/prognostic relevance, but also for monitoring therapeutic response in patients with psoriasis. This article is protected by copyright. All rights reserved.
MiR-146a-5p correlates with clinical efficacy in psoriasis patients treated with the TNF alpha inhibitor Adalimumab / Mensà, E; Recchioni, R; Marcheselli, F; Giuliodori, K; Consales, V; Molinelli, E; Prattichizzo, F; Rippo, Mr; Campanati, A; Procopio, Ad; Olivieri, F; Offidani, A M. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 1365-2133. - ELETTRONICO. - (2018). [10.1111/bjd.16659]
MiR-146a-5p correlates with clinical efficacy in psoriasis patients treated with the TNF alpha inhibitor Adalimumab
Mensà, E;Giuliodori, K;Consales, V;Molinelli, E;Prattichizzo, F;Rippo, MR;Campanati, A
;Procopio, AD;Olivieri, F;Offidani, A M
2018-01-01
Abstract
Inter-individual variability in clinical efficacy of different biological treatments in psoriatic patients, has been observed. Thus, the identification of a blood-based biomarker able to foresee the therapeutic response to treatment is urgently needed, especially considering the high cost of biological therapies. MicroRNAs (miRs) deregulation were previously observed in psoriatic patients, and increasing evidence highlighted that miRs could be novel biomarkers not only with diagnostic/prognostic relevance, but also for monitoring therapeutic response in patients with psoriasis. This article is protected by copyright. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
